Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Phosphorylation of Parkin at serine 65 is essential for its activation in vivo.

McWilliams TG, Barini E, Pohjolan-Pirhonen R, Brooks SP, Singh F, Burel S, Balk K, Kumar A, Montava-Garriga L, Prescott AR, Hassoun SM, Mouton-Liger F, Ball G, Hills R, Knebel A, Ulusoy A, Di Monte DA, Tamjar J, Antico O, Fears K, Smith L, Brambilla R, Palin E, Valori M, Eerola-Rautio J, Tienari P, Corti O, Dunnett SB, Ganley IG, Suomalainen A, Muqit MMK.

Open Biol. 2018 Nov 7;8(11). pii: 180108. doi: 10.1098/rsob.180108.

2.

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.

Bae EJ, Kim DK, Kim C, Mante M, Adame A, Rockenstein E, Ulusoy A, Klinkenberg M, Jeong GR, Bae JR, Lee C, Lee HJ, Lee BD, Di Monte DA, Masliah E, Lee SJ.

Nat Commun. 2018 Aug 27;9(1):3465. doi: 10.1038/s41467-018-05958-z.

3.

Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson's disease.

Milanese C, Cerri S, Ulusoy A, Gornati SV, Plat A, Gabriels S, Blandini F, Di Monte DA, Hoeijmakers JH, Mastroberardino PG.

Cell Death Dis. 2018 Jul 26;9(8):818. doi: 10.1038/s41419-018-0848-7.

4.

Long-lasting pathological consequences of overexpression-induced α-synuclein spreading in the rat brain.

Rusconi R, Ulusoy A, Aboutalebi H, Di Monte DA.

Aging Cell. 2018 Apr;17(2). doi: 10.1111/acel.12727. Epub 2018 Jan 30.

5.

In vivo models of alpha-synuclein transmission and propagation.

Recasens A, Ulusoy A, Kahle PJ, Di Monte DA, Dehay B.

Cell Tissue Res. 2018 Jul;373(1):183-193. doi: 10.1007/s00441-017-2730-9. Epub 2017 Nov 29. Review.

PMID:
29185072
6.

The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice.

Migdalska-Richards A, Wegrzynowicz M, Rusconi R, Deangeli G, Di Monte DA, Spillantini MG, Schapira AHV.

Brain. 2017 Oct 1;140(10):2706-2721. doi: 10.1093/brain/awx221.

7.

Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP.

Schildknecht S, Di Monte DA, Pape R, Tieu K, Leist M.

Trends Pharmacol Sci. 2017 Jun;38(6):541-555. doi: 10.1016/j.tips.2017.03.010. Epub 2017 Apr 23. Review.

PMID:
28442167
8.

Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections.

Ulusoy A, Phillips RJ, Helwig M, Klinkenberg M, Powley TL, Di Monte DA.

Acta Neuropathol. 2017 Mar;133(3):381-393. doi: 10.1007/s00401-016-1661-y. Epub 2016 Dec 23.

9.

Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice.

Helwig M, Klinkenberg M, Rusconi R, Musgrove RE, Majbour NK, El-Agnaf OM, Ulusoy A, Di Monte DA.

Brain. 2016 Mar;139(Pt 3):856-70. doi: 10.1093/brain/awv376. Epub 2015 Dec 30.

PMID:
26719384
10.

Mesenchymal stromal SB623 cell implantation mitigates nigrostriatal dopaminergic damage in a mouse model of Parkinson's disease.

Tate CC, Chou VP, Campos C, Moalem AS, Di Monte DA, McGrogan M, Case CC, Manning-Bog AB.

J Tissue Eng Regen Med. 2017 Jun;11(6):1835-1843. doi: 10.1002/term.2081. Epub 2015 Oct 6.

PMID:
26440859
11.

Function and developmental origin of a mesocortical inhibitory circuit.

Kabanova A, Pabst M, Lorkowski M, Braganza O, Boehlen A, Nikbakht N, Pothmann L, Vaswani AR, Musgrove R, Di Monte DA, Sauvage M, Beck H, Blaess S.

Nat Neurosci. 2015 Jun;18(6):872-82. doi: 10.1038/nn.4020. Epub 2015 May 11.

PMID:
25961790
12.

Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury.

Ulusoy A, Musgrove RE, Rusconi R, Klinkenberg M, Helwig M, Schneider A, Di Monte DA.

Acta Neuropathol Commun. 2015 Mar 24;3:13. doi: 10.1186/s40478-015-0198-y.

13.

Neurodegeneration by activation of the microglial complement-phagosome pathway.

Bodea LG, Wang Y, Linnartz-Gerlach B, Kopatz J, Sinkkonen L, Musgrove R, Kaoma T, Muller A, Vallar L, Di Monte DA, Balling R, Neumann H.

J Neurosci. 2014 Jun 18;34(25):8546-56. doi: 10.1523/JNEUROSCI.5002-13.2014.

14.

Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation.

Pérez-Revuelta BI, Hettich MM, Ciociaro A, Rotermund C, Kahle PJ, Krauss S, Di Monte DA.

Cell Death Dis. 2014 May 8;5:e1209. doi: 10.1038/cddis.2014.175.

15.

Caudo-rostral brain spreading of α-synuclein through vagal connections.

Ulusoy A, Rusconi R, Pérez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, Di Monte DA.

EMBO Mol Med. 2013 Jul;5(7):1119-27. doi: 10.1002/emmm.201302475. Epub 2013 May 23.

16.

Evidence of oxidative stress in young and aged DJ-1-deficient mice.

Raman AV, Chou VP, Atienza-Duyanen J, Di Monte DA, Bellinger FP, Manning-Boğ AB.

FEBS Lett. 2013 May 21;587(10):1562-70. doi: 10.1016/j.febslet.2013.04.001. Epub 2013 Apr 13.

17.

Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.

Schildknecht S, Gerding HR, Karreman C, Drescher M, Lashuel HA, Outeiro TF, Di Monte DA, Leist M.

J Neurochem. 2013 May;125(4):491-511. doi: 10.1111/jnc.12226. Epub 2013 Mar 19. Review.

18.

α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications.

Ulusoy A, Di Monte DA.

Mol Neurobiol. 2013 Apr;47(2):484-94. doi: 10.1007/s12035-012-8329-y. Epub 2012 Sep 4. Review.

PMID:
22944910
19.

Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra.

McCormack AL, Mak SK, Di Monte DA.

Cell Death Dis. 2012 May 31;3:e315. doi: 10.1038/cddis.2012.50.

20.

Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease.

Zachrisson O, Zhao M, Andersson A, Dannaeus K, Häggblad J, Isacson R, Nielsen E, Patrone C, Rönnholm H, Wikstrom L, Delfani K, McCormack AL, Palmer T, Di Monte DA, Hill MP, Janson Lang AM, Haegerstrand A.

J Parkinsons Dis. 2011;1(1):49-63. doi: 10.3233/JPD-2011-0003.

PMID:
23939256
21.

Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra.

McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA.

PLoS One. 2010 Aug 11;5(8):e12122. doi: 10.1371/journal.pone.0012122.

22.

Gene-environment interactions in Parkinson's disease and other forms of parkinsonism.

Vance JM, Ali S, Bradley WG, Singer C, Di Monte DA.

Neurotoxicology. 2010 Sep;31(5):598-602. doi: 10.1016/j.neuro.2010.04.007. Epub 2010 Apr 27. Review.

PMID:
20430055
23.

Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.

Lou H, Montoya SE, Alerte TN, Wang J, Wu J, Peng X, Hong CS, Friedrich EE, Mader SA, Pedersen CJ, Marcus BS, McCormack AL, Di Monte DA, Daubner SC, Perez RG.

J Biol Chem. 2010 Jun 4;285(23):17648-61. doi: 10.1074/jbc.M110.100867. Epub 2010 Mar 31.

24.

Lysosomal degradation of alpha-synuclein in vivo.

Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA.

J Biol Chem. 2010 Apr 30;285(18):13621-9. doi: 10.1074/jbc.M109.074617. Epub 2010 Mar 3.

25.

Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions.

Zhou W, Long C, Reaney SH, Di Monte DA, Fink AL, Uversky VN.

Biochim Biophys Acta. 2010 Mar;1802(3):322-30. doi: 10.1016/j.bbadis.2009.12.004. Epub 2009 Dec 21.

26.

Decreased alpha-synuclein expression in the aging mouse substantia nigra.

Mak SK, McCormack AL, Langston JW, Kordower JH, Di Monte DA.

Exp Neurol. 2009 Dec;220(2):359-65. doi: 10.1016/j.expneurol.2009.09.021. Epub 2009 Oct 1.

PMID:
19800328
27.

Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications.

McCormack AL, Di Monte DA.

Curr Protein Pept Sci. 2009 Oct;10(5):476-82. Review.

PMID:
19538156
28.

Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, Liu Y, Qian L, Wilson B, Di Monte DA, Ali SF, Zhang J, Block ML, Hong JS.

J Immunol. 2008 Nov 15;181(10):7194-204.

29.

Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys.

McCormack AL, Mak SK, Shenasa M, Langston WJ, Forno LS, Di Monte DA.

J Neuropathol Exp Neurol. 2008 Aug;67(8):793-802. doi: 10.1097/NEN.0b013e318180f0bd.

30.

Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum.

O'Leary KT, Parameswaran N, Johnston LC, McIntosh JM, Di Monte DA, Quik M.

J Pharmacol Exp Ther. 2008 Oct;327(1):124-9. doi: 10.1124/jpet.108.141861. Epub 2008 Jul 7.

31.

MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.

Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, Di Monte DA, Macarthur H, Andersen JK.

PLoS One. 2008 Feb 20;3(2):e1616. doi: 10.1371/journal.pone.0001616. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/3c37bef4-bb5e-4f1e-8551-01afc006df90.

32.

Letter regarding: "Paraquat: the red herring of Parkinson's disease research".

Cory-Slechta DA, Thiruchelvam M, Di Monte DA.

Toxicol Sci. 2008 May;103(1):215-6; author reply 217-8. Epub 2007 Dec 27. No abstract available.

PMID:
18162474
33.

Paraquat neurotoxicity is mediated by a Bak-dependent mechanism.

Fei Q, McCormack AL, Di Monte DA, Ethell DW.

J Biol Chem. 2008 Feb 8;283(6):3357-64. Epub 2007 Dec 4.

34.

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.

Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, Miller GW.

J Neurosci. 2007 Jul 25;27(30):8138-48.

35.

The etiopathogenesis of Parkinson disease and suggestions for future research. Part II.

Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D Jr, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, Duyckaerts C, Dickson DW, Ben-Shlomo Y, Goetz CG, Melamed E.

J Neuropathol Exp Neurol. 2007 May;66(5):329-36. Review.

PMID:
17483689
36.

The etiopathogenesis of Parkinson disease and suggestions for future research. Part I.

Litvan I, Halliday G, Hallett M, Goetz CG, Rocca W, Duyckaerts C, Ben-Shlomo Y, Dickson DW, Lang AE, Chesselet MF, Langston WJ, Di Monte DA, Gasser T, Hagg T, Hardy J, Jenner P, Melamed E, Myers RH, Parker D Jr, Price DL.

J Neuropathol Exp Neurol. 2007 Apr;66(4):251-7. Review. No abstract available.

PMID:
17413315
37.

The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.

Cox H, Togasaki DM, Chen L, Langston JW, Di Monte DA, Quik M.

Exp Neurol. 2007 May;205(1):101-7. Epub 2007 Feb 3.

38.

Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system.

Hatcher JM, Richardson JR, Guillot TS, McCormack AL, Di Monte DA, Jones DP, Pennell KD, Miller GW.

Exp Neurol. 2007 Apr;204(2):619-30. Epub 2007 Jan 5.

39.

Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs.

Khwaja M, McCormack A, McIntosh JM, Di Monte DA, Quik M.

J Neurochem. 2007 Jan;100(1):180-90.

40.

Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.

Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL.

J Biol Chem. 2007 Feb 23;282(8):5862-70. Epub 2006 Dec 21.

41.

Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration.

Purisai MG, McCormack AL, Cumine S, Li J, Isla MZ, Di Monte DA.

Neurobiol Dis. 2007 Feb;25(2):392-400. Epub 2006 Dec 12.

42.

Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration.

Peng J, Xie L, Stevenson FF, Melov S, Di Monte DA, Andersen JK.

J Neurosci. 2006 Nov 8;26(45):11644-51.

43.

Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures.

Reaney SH, Johnston LC, Langston WJ, Di Monte DA.

Exp Neurol. 2006 Dec;202(2):434-40. Epub 2006 Aug 22.

PMID:
16920101
44.

Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.

Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, Kim A, Tyndale RF, Langston JW, Di Monte DA.

J Neurochem. 2006 Sep;98(6):1866-75. Epub 2006 Aug 1.

45.

Lack of nigrostriatal pathology in a rat model of proteasome inhibition.

Manning-Boğ AB, Reaney SH, Chou VP, Johnston LC, McCormack AL, Johnston J, Langston JW, Di Monte DA.

Ann Neurol. 2006 Aug;60(2):256-60.

PMID:
16862576
46.

Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age.

Kaur D, Peng J, Chinta SJ, Rajagopalan S, Di Monte DA, Cherny RA, Andersen JK.

Neurobiol Aging. 2007 Jun;28(6):907-13. Epub 2006 Jun 12.

PMID:
16765489
47.

Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration.

McCormack AL, Atienza JG, Langston JW, Di Monte DA.

Neuroscience. 2006 Aug 25;141(2):929-37. Epub 2006 May 4.

PMID:
16677770
48.

Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.

Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA.

Neurobiol Dis. 2005 Dec;20(3):898-906. Epub 2005 Jul 11.

PMID:
16006134
49.

The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates.

Togasaki DM, Hsu A, Samant M, Farzan B, DeLanney LE, Langston JW, Di Monte DA, Quik M.

J Neurosci Methods. 2005 Jun 30;145(1-2):159-66.

PMID:
15922034
50.

Toxicity of redox cycling pesticides in primary mesencephalic cultures.

Bonneh-Barkay D, Langston WJ, Di Monte DA.

Antioxid Redox Signal. 2005 May-Jun;7(5-6):649-53.

PMID:
15890009

Supplemental Content

Loading ...
Support Center